A Phase 1 interventional study of Blood Oxygen Level Dependent [BOLD] MRI and Diffusion-Weighted [DW] MRI in Rhabdomyosarcoma and Non-Rhabdo. Soft Tissue Sarcoma, sponsored by The Hospital for Sick Children. Enrolling by invitation at 1 site in Canada. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by The Hospital for Sick Children · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Rhabdomyosarcoma with a site in Canada — 4 open to participants now, 9 under way, 3 of them phase 3. Rhabdomyosarcoma · Canada.
Among the 32 studies in Rhabdomyosarcoma with a site in Canada, this one is the 27th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 1, and was the 23rd registered.
238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.
Browse Rhabdomyosarcoma studies →4 of the 32 studies in Rhabdomyosarcoma with a site in Canada are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in Canada, United States
Ages up to 50
Milton S. Hershey Medical Center · Sites in Canada, United States
Ages up to 30
St. Jude Children's Research Hospital · Sites in Canada, United States
Ages 12 mo–30 yrs
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; none take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 9
First in 1995; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 42 across 202 interventional studies indexed under Rhabdomyosarcoma.
Median enrollment 106 across the 30 interventional studies, 182 across the 2 observational. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 32 have an industry lead sponsor. The 10 most frequent:
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
The Hospital for Sick Children has 1 study filed under Rhabdomyosarcoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Rhabdomyosarcoma with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03054792The Hospital for Sick ChildrenMolecular-Functional Imaging of Hypoxia in Childhood Sarcomas | 2026-12 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT03478462Cellectar Biosciences, Inc.Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Rhabdomyosarcoma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI and Magnetic Resonance Spectroscopy (MRS) with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (6-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI, MR Spectroscopy \[MRS\]
Diagnostic Test: Blood Oxygen Level Dependent [BOLD] MRI · Diagnostic Test: Diffusion-Weighted [DW] MRI · Diagnostic Test: Magnetic Resonance Spectroscopy [MRS]
BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
Number of participants with response to therapy
Response will be assessed by measurements of tumor volume, percentage of BOLD signal changes, percentage of tumor necrosis, apparent diffusion coefficient, concentration of high-energy and low-energy phosphates in tumor.
Time frame: 1 year
Associations between post-neoadjuvant therapy imaging measurements and surgical / histochemical outcomes in the residual tumor.
Time frame: 1 year
Plan to share: No — No IPD data will be shared with other researchers
No publications or documents are linked to this record.
Started May 2017 (actual). Primary completion is estimated for Dec 2026, 115 months after the start.
Of 38 phase 1 interventional studies under Rhabdomyosarcoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 134. This study's planned 115 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →